Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome? A new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480
Article
Google Scholar
ALLHAT (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). Jama 283:1967–1975
Article
Google Scholar
Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642–1649
Article
Google Scholar
Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D (2001) Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C (Appl Stat) 50(4):405–422
Article
MathSciNet
MATH
Google Scholar
Buyse M, Molenberghs G (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54(3):1014–1029
Article
MATH
Google Scholar
Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25(33):5218–5224
Article
Google Scholar
Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A et al (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Lancet 351(9102):543–549
Article
Google Scholar
Choi S, Lagakos SW, Schooley RT, Volberding PA (1993) Cd4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 118(9):674–680
Article
Google Scholar
Conlon AS, Taylor JM, Elliott MR (2014) Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal. Biostatistics 15(2):266–283
Article
Google Scholar
Eastwood JA, Doering LV (2005) Gender differences in coronary artery disease. J Cardiovasc Nurs 20(5):340–351
Article
Google Scholar
Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M (1997) Impact of new antiretroviral combination therapies in HIV infected patients in switzerland: prospective multicentre study. Bmj 315(7117):1194–1199
Article
Google Scholar
Elliott MR, Conlon AS, Li Y, Kaciroti N, Taylor JM (2015) Surrogacy marker paradox measures in meta-analytic settings. Biostatistics 16(2):400–412
Article
MathSciNet
Google Scholar
FDA (2008) Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf. Accessed 9 Apr 2019
Fleming TR, Prentice RL, Pepe MS, Glidden D (1994) Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and aids research. Stat Med 13(9):955–968
Article
Google Scholar
Frangakis CE, Rubin DB (2002) Principal stratification in causal inference. Biometrics 58(1):21–29
Article
MathSciNet
MATH
Google Scholar
Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11(2):167–178
Article
Google Scholar
Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A (2013) Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract 102(2):86–95
Article
Google Scholar
Gabriel EE, Sachs MC, Gilbert PB (2015) Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints. Stat Med 34(3):381–395
Article
MathSciNet
Google Scholar
Ghosh D (2008) Semiparametric inference for surrogate endpoints with bivariate censored data. Biometrics 64(1):149–156
Article
MathSciNet
MATH
Google Scholar
Ghosh D (2009) On assessing surrogacy in a single trial setting using a semicompeting risks paradigm. Biometrics 65(2):521–529
Article
MathSciNet
MATH
Google Scholar
Gilbert PB, Hudgens MG (2008) Evaluating candidate principal surrogate endpoints. Biometrics 64(4):1146–1154
Article
MathSciNet
MATH
Google Scholar
Hammer S, Katzenstein D, Hughes M, Gundacker H, Schooley R, Haubrich R, Henry W, Lederman M, Phair J, Niu M et al (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 335(15):1081–1090
Article
Google Scholar
Huang Y, Gilbert PB (2011) Comparing biomarkers as principal surrogate endpoints. Biometrics 67(4):1442–1451
Article
MathSciNet
MATH
Google Scholar
Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT (1998) Cd4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the aids clinical trials group. Aids 12(14):1823–1832
Article
Google Scholar
Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T, Collaboration CKDE et al (2014) Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64(1):74–85
Article
Google Scholar
Jordan R, Gold L, Cummins C, Hyde C (2002) Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Bmj 324(7340):757
Article
Google Scholar
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H et al (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet 353(9156):863–868
Article
Google Scholar
Lin D, Fischl MA, Schoenfeld D (1993) Evaluating the role of cd4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 12(9):835–842
Article
Google Scholar
Lin D, Fleming T, De Gruttola V et al (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16(13):1515–1527
Article
Google Scholar
Lorenzo C, Williams K, Stern MP, Haffner SM (2003) The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care 26(11):3153–3159
Article
Google Scholar
Maas A, Appelman Y (2010) Gender differences in coronary heart disease. Neth Heart J 18(12):598–603
Article
Google Scholar
NHLBI (2008) NHLBI data repository: prevention of events with angiotensin-converting enzyme inhibitor therapy (peace). https://biolincc.nhlbi.nih.gov/studies/peace/. Accessed 9 Apr 2019
Parast L, Cai T (2013) Landmark risk prediction of residual life for breast cancer survival. Stat Med 32(20):3459–3471. https://doi.org/10.1002/sim.5776
MathSciNet
Article
Google Scholar
Parast L, McDermott MM, Tian L (2016) Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med 35(10):1637–1653
Article
MathSciNet
Google Scholar
Parast L, Cai T, Tian L (2017) Evaluating surrogate marker information using censored data. Stat Med 36(11):1767–1782
Article
MathSciNet
Google Scholar
PEACE (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004(351):2058–2068
Google Scholar
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293–1304
Article
Google Scholar
Robins JM, Greenland S (1992) Identifiability and exchangeability for direct and indirect effects. Epidemiology 3(2):143–155
Article
Google Scholar
Royston P, Parmar MK (2011) The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 30(19):2409–2421
Article
MathSciNet
Google Scholar
Royston P, Parmar MK (2013) Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13(1):152
Article
Google Scholar
Stevens LA, Greene T, Levey AS (2006) Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1(4):874–884
Article
Google Scholar
Tian L, Zhao L, Wei L (2013) Predicting the restricted mean event time with the subject’s baseline covariates in survival analysis. Biostatistics 15(2):222–233
Article
Google Scholar
Van der Weele TJ (2013) Surrogate measures and consistent surrogates. Biometrics 69(3):561–565
Article
MathSciNet
MATH
Google Scholar
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. The Lancet 364(9440):1127–1134
Article
Google Scholar
Wang Y, Taylor JM (2002) A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 58(4):803–812
Article
MathSciNet
MATH
Google Scholar
Wittes J, Lakatos E, Probstfield J (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8(4):415–425
Article
Google Scholar